Deze website maakt gebruik van cookies

Deze website gebruikt cookies en verzamelt daarmee informatie over het gebruik van de website om deze te analyseren en om er voor te zorgen dat je voor jou relevante informatie en advertenties te zien krijgt. Door hiernaast op akkoord te klikken, geef je aan akkoord te zijn met het gebruik van cookies en het verzamelen van informatie aan de hand daarvan door ons en door derden. Bezoek onze privacyverklaring voor meer informatie over persoonlijke voorkeuren.

Akkoord
Niet akkoord
News

Leading Dutch biochip companies accelerate development of  fast and reliable COVID-19 test.

24 APRIL 2020

Surfix B.V., together with its shareholders Qurin Diagnostics B.V. and LioniX International B.V., already successfully developing bio-photonic nanochips for cancer detection and other applications, today announce an accelerated development plan to allow mass-scale COVID-19 diagnosis and immunity detection with the financial support and in close collaboration with PhotonDelta.

The desktop testing device will yield reliable test results within 5 minutes and is scheduled to be available for commercial exploitation within 6-9 months. The device will be built around a photonic biochip using LioniX’ mature and proven silicon nitride based integrated optics technology (TriPleX™), a key technology within the PhotonDelta ecosystem. The surface functionalization and biochemical assay development are provided by Surfix and Qurin Diagnostics, respectively. The combination of these disciplines enables a successful, fast and accurate virus detection platform. The development will be supported by and in tight collaboration with PhotonDelta (a Dutch public private partnership). The PhotonDelta support will be both in co-funding as in further future upscaling and exploitation.

Qurin Diagnostics, Surfix and LioniX International  are already working together closely on early cancer detection and have realized an ultra-sensitive biochip sensor array which will be applied for early cancer detection using urine as a liquid biopsy

A strategic collaboration

Coenraad K. van Kalken, CEO of Qurin Diagnostics, said ”This collaboration confirms our strategic vision that the ultrasensitive biochip we’re jointly developing for mass scale, low-cost cancer screening is broadly applicable in  biological agri-food markets as well as in other biomedical fields. All these fields need highly accurate molecular diagnosis technology at lower cost than complex and labor intensive molecular technologies, currently used.”
 
Luc Scheres CTO of Surfix said “We have developed specific nanocoatings which enhance the sensitivity, limit of detection and reliability of the photonic biochip. Of course every application comes with its own specific challenges and demands, so close collaboration with experts from other disciplines is essential to successfully develop a diagnostic test. Therefore, we are happy to strengthen our collaboration with LioniX International and Qurin Diagnostics for the accelerated development of a corona virus test.”
 
“The TriPleX™ platform has shown its capabilities and possibilities for high volume cost effective cancer diagnostics and investing in this new application is not merely a commercial driven choice, but also driven by societal importance. Since we have a solid technology base and reliable collaboration partners, who also enabled the cancer diagnostics measurements, we have large confidence in realizing a successful COVID-19 test.”, said Arne Leinse, CEO of LioniX International.
 
“‘This is a great example of a joint effort of partners in the PhotonDelta ecosystem to develop meaningful, low costs and effective solutions enabled with integrated photonics technology. The initiative builds upon our knowledge on ultra-sensitive biochips, which might be of utmost relevance in detecting the current COVID-19 crisis. Bio sensing is one of the long-term development programs (roadmap) within PhotonDelta where industry, universities and the entire PhotonDelta ecosystem work together on next generation solutions and testing devices on viruses and other diseases‘’, said Ewit Roos, CEO of PhotonDelta 

This is a great example of a joint effort of partners in the PhotonDelta ecosystem to develop meaningful, low costs and effective solutions enabled with integrated photonics technology. - Ewit Roos, CEO of PhotonDelta

Links
Adres

High Tech Campus 41
5656 AE Eindhoven
The Netherlands

Contact

+31 (0)85 112 43 37

office@photondelta.eu

© 2019 PhotonDelta